Vivo Opportunity entities disclose 9.99% Pasithea Therapeutics (KTTA) holdings via warrants and stock
Pasithea Therapeutics Corp. (KTTA) disclosed in an SEC Schedule 13G/A that Vivo Opportunity entities hold just under 10% of its common stock. Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P. each report 9.99% beneficial ownership, including common shares and pre-funded warrants. The filing cites 33,414,448 shares outstanding as of May 13, 2026.
How this was made
The 30-second read
Why it matters
This is primarily a positioning and potential control/dilution read-through. The key incremental detail is the warrant structure that blocks exercise above 9.99% while the reported amounts assume full exercise for disclosure purposes.
Market read
Traders may use the near-10% stake and warrant cap to gauge potential strategic interest and future dilution risk, but there is no new clinical, regulatory, or financing event described.
What to watch
Beneficial ownership includes shares issuable upon warrant exercise without applying the cap, so the economic exposure may be larger than the voting exposure; traders should monitor subsequent amendments for actual exercise or cap-related adjustments.
Background
The article summarizes a Schedule 13G/A disclosure by Vivo Opportunity entities reporting beneficial ownership in Pasithea Therapeutics, including pre-funded warrants with a 9.99% ownership/voting threshold.
Ticker impact
Pasithea Therapeutics discloses Vivo Opportunity entities holding 9.99% via common shares plus pre-funded warrants, with a 9.99% voting cap.
Near-term price impact is likely limited unless follow-on filings or activism emerge; watch for changes in ownership structure or warrant exercise behavior.
The article is a Schedule 13G/A style disclosure of beneficial ownership and warrant terms, not a new operational catalyst. The 9.99% threshold and blocking provisions are specific, but the filing alone does not indicate intent to exercise or take control.
Market effects
For small-cap biotech, large near-threshold ownership disclosures can signal financing or strategic interest, but this filing alone does not change clinical or regulatory expectations.
None indicated.
None indicated.
Counterpoint
The 9.99% cap and blocking provisions suggest the holder is intentionally avoiding crossing a control threshold, which may reduce the likelihood of immediate governance or activist pressure.
Key entities
- issuerPasithea Therapeutics Corp.
Subject of the Schedule 13G/A disclosure; common stock outstanding 33,414,448 shares as of May 13, 2026.
- reporting_personVivo Opportunity Fund Holdings, L.P.
Reports 9,286,738 beneficially owned shares, equal to 9.99%, including common shares and pre-funded warrants.
- reporting_personVivo Opportunity Cayman Fund, L.P.
Reports 937,567 beneficially owned shares, equal to 9.99%, including common shares and pre-funded warrants.
